Skip to main content
. 2020 Mar 31;29(5):474–481. doi: 10.1177/0961203320909156

Table 2.

Clinical features of the different age groups over time

Items on last follow up Pre-pubertal disease-onset (n = 43) Peri-pubertal disease-onset (n = 240) Adolescence (n = 135) p value
Length of follow up in years 6 [3–9] 4 [2–6] 2 [1–4] <0.001
Total ACR score 5 [4–7] 5 [4–7] 5 [4–7] 0.686
SLICC-SDI score 0 [0–1] 0 [0–1] 0 [0–1] 0.284
SLEDAI-2 K 8 [5–8] 8 [6–8] 7 [5–8] 0.689
ANA positivity 42 (97.7%) [93.2%, 102.2%] 230 (95.8%) [93.3%, 98.3%] 132 (97.8%) [95.3%, 100.0%] 0.559
pBILAG2004 defined organ/system domain involvement throughout the disease course
 Constitutional 18 (41.9%) [27.2%, 56.6%] 98 (40.8%) [34.1%, 46.5%] 56 (41.5%) [33.2%, 49.8%] 0.988
 Mucocutaneous 33 (76.7%) [64.1%, 89.3%] 157 (65.4%) [59.4%, 71.4%] 90 (66.7%) [58.7%, 74.7%] 0.346
 Neuropsychiatric 11 (25.6%) [12.6%, 38.6%] 57 (27.9%) [22.2%, 33.6%] 28 (20.7%) [13.9%, 27.5%] 0.731
 Musculoskeletal 18 (41.9%) [16.5%, 43.9%] 121 (50.4%) [44.1%, 56.7%] 73 (54.1%) [45.7%, 62.5%] 0.374
 Cardiorespiratory 13 (30.2%) [16.5%, 43.9%] 46 (19.2%) [14.2%, 24.2%] 35 (25.9%) [18.5%, 33.3%] 0.141
 Gastrointestinal 8 (18.6%) [7.0%, 30.2%] 28 (11.7%) [7.6%, 15.8%] 10 (7.4%) [3.0%, 11.8%] 0.107
 Ophthalmic 3 (7.0%) [0%, 14.6%] 12 (5.0%) [2.2%, 7.8%] 4 (3.0%) [0.1%, 5.9%] 0.467
 Renal 28 (65.1%) [50.9%, 79.3%] 153 (63.8%) [57.7%, 69.9%] 94 (69.6%) [61.8%, 77.4%] 0.513
 Haematological 26 (60.5%) [45.9%, 75.1%] 114 (47.5%) [41.2%, 53.8%] 55 (40.7%) [32.4%, 49.0%] 0.072

Total ACR, SLICC-SDI, SLEDAI-2 K, pBILAG2004 scores are reported as median values and interquartile ranges. For individual pBILAG2004 domains, the total number of patients with activity involvement (defined as a pBILAG2004 domain score of A or B in a given organ domain/system) are provided along with percentage (in curved brackets), and 95% confidence intervals for the percentage [square brackets]. SLICC-SDI and ACR scores are provided from the last follow-up visit.

ACR, American College of Rheumatology; ANA, antinuclear antibodies; BILAG, British Isles Lupus Assessment Group; SLICC-SDI, Systemic Lupus International Collaborating Clinics-standardised damage index; SLEDAI-2 K, Systemic Lupus Erythematosus Disease Activity Index 2000.